2 results
Approved WMOCompleted
Improvement in OS is generally accepted as the best measure of clinical benefit forpatients with advanced/unresectable or metastatic NSCLC. The assumption thattreatment with MPDL3280A will prolong OS compared with treatment with docetaxel isbased on…
BioXmark liquid fiducial to enable radiotherapy tumor boosting in rectal cancer, a feasibility trial
To test the feasibility and accuracy of BioXmark fiducial markers for IGRT based rectal tumor boosting.